Targets › IL4R
13 programs from 13 companies in 159 trials: 61 Phase 2, 36 Phase 4, 33 Phase 3, 29 Phase 1; Immunology, Respiratory, Gastroenterology; next expected readout Nov 2026.
Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. (UniProt, P24394)
Open in Phaseline: the race on IL4R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| Regeneron Pharmaceuticals | dupilumab Interleukin-4 receptor subunit alpha antagonist | IL4R | Phase 4 | Asthma; Chronic Obstructive Pulmonary Disease (COPD); Atopic Dermatitis; Eosinophilic Esophagitis (EoE) … | Nov 2026 |
| Sanofi | H5 Flu IMP 1 Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1, TNFSF4, CD38, IL4R | Phase 4 | RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic … | Dec 2026 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQH2722 injection Humanized interleukin-4 receptor alpha (IL-4Rα) monoclonal antibody | IL4R | Phase 3 | Atopic Dermatitis; Seasonal Allergic Rhinitis | Nov 2026 |
| Guangdong Hengrui Pharmaceutical | SHR-1819 Injection IL-4 receptor alpha inhibitor | IL4R | Phase 3 | Seasonal Allergic Rhinitis; Adolescents With Moderate-to-severe Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; Prurigo Nodularis | Dec 2026 |
| Jiangsu Genscend Biopharmaceutical | GS101 injection IL-4 receptor alpha subunit antagonist | IL4R | Phase 3 | Atopic Dermatitis (AD) | Apr 2027 |
| Université de Sherbrooke | CBD Oral Solution FK506-binding protein 1A inhibitor | FKBP1A, PTGS2, IL4R | Phase 3 | Asthma Control; Organ Transplant Failure or Rejection; Fragile X Syndrome; Triple-Negative Breast Cancer | Jul 2028 |
| Innovent Biologics (Suzhou) | IBI3027 IL-4 receptor alpha antagonist (anti-IL-4Rα antibody) | IL4R | Phase 3 | Atopic Dermatitis; Healthy Volunteers | Jul 2028 |
| Keymed Biosciences Co.Ltd | CM310 IL-4 receptor (IL-4Rα) monoclonal antibody | IL4R | Phase 3 | Atopic Dermatitis | – |
| Genrix (Shanghai) Biopharmaceutical | GR1802 anti-IL4Rα monoclonal antibody | IL4R | Phase 3 | Allergic Rhinitis, Seasonal; Chronic Rhinosinusitis With Nasal Polyps; Allergic Rhinitis | – |
| Apogee Therapeutics | APG777 IL-4 receptor antagonist | IL4R | Phase 2 | Atopic Dermatitis; Asthma | Nov 2026 |
| Uniquity One (UNI) | Solrikitug IL-4 receptor alpha inhibitor | IL4R | Phase 2 | COPD; Eosinophilic Esophagitis (EoE) | Feb 2027 |
| Beijing Tongren Hospital | CM310 Interleukin-4 receptor antagonist | IL4R | Phase 2 | Seasonal Allergic Rhinitis | – |
Atopic Dermatitis (11) Asthma (8) Dermatitis Atopic (5) Ulcerative Colitis (4) Colitis Ulcerative (4) Nasal Polyps (4) Obstructive Sleep Apnea (4) Seasonal Allergic Rhinitis (3) Chronic Graft Versus Host Disease (3) Crohn's Disease (3) Plasma Cell Myeloma Refractory (3) Healthy Volunteers (3)
small molecule (6), protein or peptide (4), antibody (2), mixed (1)
Apogee Therapeutics (1) Guangdong Hengrui Pharmaceutical (1) Sanofi (1) Université de Sherbrooke (1) Keymed Biosciences Co.Ltd (1) Regeneron Pharmaceuticals (1) Brigham and Women's Hospital (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Innovent Biologics (Suzhou) (1) Uniquity One (UNI) (1) Jiangsu Genscend Biopharmaceutical (1) Genrix (Shanghai) Biopharmaceutical (1) Beijing Tongren Hospital (1)
ROCK2 (1) ROCK1 (1) TNFSF4 (1) CD38 (1) FKBP1A (1) PTGS2 (1) SLC5A2 (1) SLC6A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) OPRM1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.